Definium Therapeutics to Participate at Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)-- Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.), (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences:

• TD Cowen 46th Annual Health Care Conference
  • Presentation Date and Time: Monday, March 2, 2026 at 9:10 AM ET
  • Location: Boston, MA
  • Webcast Link: TD Cowen 46th Annual Health Care Conference
• Jefferies Biotech on the Beach Summit
  • Date: Tuesday, March 10, 2026
  • Location: Miami Beach, FL
• Leerink Partners Global Healthcare Conference
  • Fireside Chat Date and Time: Wednesday, March 11, 2026 at 1:00 PM ET
  • Location: Miami Beach, FL
  • Webcast Link: Leerink Partners Global Healthcare Conference
• Stifel 2026 Virtual CNS Forum
  • Fireside Chat Date and Time: Tuesday, March 17, 2026 at 3:30 PM ET
  • Location: Virtual
  • Webcast Link: Stifel 2026 Virtual CNS Forum

Audio webcasts and replays of available presentations will be accessible on Definium’s Investor Relations website for up to 90 days following each event.

About Definium Therapeutics

The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Guided by a recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today’s mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX.

For more information, visit https://definiumtx.com/ and follow Definium Therapeutics on Instagram, LinkedIn and X.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260224354689/en/

Investor Contact:
Gitanjali Jain
VP, Head of Investor Relations
[email protected]

Media Contact:
[email protected]

Source: Definium Therapeutics, Inc.

You May Also Be Interested In

• Yatra Confirms Commencement of Unsolicited Partial Tender Offer by Magna Holdings Ltd.
• Sabeer Nelli Calls Operational Readiness a Missing Step in Small-Business Growth Plans
• Charmin is Officially Putting Bad Roommate Bathroom Behavior on Trial with the Forever Roll